• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pheochromocytoma - Pipeline Review, H2 2012 Product Image

Pheochromocytoma - Pipeline Review, H2 2012

  • Published: November 2012
  • 41 pages
  • Global Markets Direct

Pheochromocytoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pheochromocytoma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pheochromocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pheochromocytoma. Pheochromocytoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pheochromocytoma.
- A review of the Pheochromocytoma products under development by companies and universities/research institutes READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Pheochromocytoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Pheochromocytoma 7
Pheochromocytoma Therapeutics under Development by Companies 9
Pheochromocytoma Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pheochromocytoma Therapeutics – Products under Development by Companies 14
Pheochromocytoma Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Pheochromocytoma Therapeutics Development 16
Molecular Insight Pharmaceuticals, Inc. 16
Pheochromocytoma – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
iobenguane I 131 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
pazopanib hydrochloride - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
nelfinavir mesylate - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
sunitinib malate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
everolimus - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
I-131 Metaiodobenzyl Guanidine + 6-[18F] Fluorodopamine + I-123 Metaiodobenzyl Guanidine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
IMC-A12 + Octreotide + Everolimus - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 34
fostamatinib disodium - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
sunitinib malate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Dovitinib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Pheochromocytoma Therapeutics – Drug Profile Updates 38
Pheochromocytoma Therapeutics - Dormant Products 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Pheochromocytoma, H2 2012 7
Products under Development for Pheochromocytoma – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Molecular Insight Pharmaceuticals, Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Pheochromocytoma Therapeutics – Drug Profile Updates 38
Pheochromocytoma Therapeutics – Dormant Products 39

List of Figures
Number of Products under Development for Pheochromocytoma, H2 2012 7
Products under Development for Pheochromocytoma – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos